TR201902875T4 - Plk-4 inhibitörünün tuz ve kristal formları. - Google Patents
Plk-4 inhibitörünün tuz ve kristal formları. Download PDFInfo
- Publication number
- TR201902875T4 TR201902875T4 TR2019/02875T TR201902875T TR201902875T4 TR 201902875 T4 TR201902875 T4 TR 201902875T4 TR 2019/02875 T TR2019/02875 T TR 2019/02875T TR 201902875 T TR201902875 T TR 201902875T TR 201902875 T4 TR201902875 T4 TR 201902875T4
- Authority
- TR
- Turkey
- Prior art keywords
- compound
- salt
- fumarate
- cancer
- weight
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892564P | 2013-10-18 | 2013-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201902875T4 true TR201902875T4 (tr) | 2019-03-21 |
Family
ID=52827507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/02875T TR201902875T4 (tr) | 2013-10-18 | 2014-10-17 | Plk-4 inhibitörünün tuz ve kristal formları. |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US9884855B2 (enExample) |
| EP (1) | EP3057965B1 (enExample) |
| JP (1) | JP6492072B2 (enExample) |
| KR (3) | KR20160070106A (enExample) |
| CN (2) | CN105764899B (enExample) |
| AU (1) | AU2014336929B9 (enExample) |
| CA (1) | CA2926845C (enExample) |
| CY (1) | CY1121484T1 (enExample) |
| DK (1) | DK3057965T3 (enExample) |
| EA (1) | EA031569B1 (enExample) |
| ES (1) | ES2718603T3 (enExample) |
| HR (1) | HRP20190564T1 (enExample) |
| HU (1) | HUE043194T2 (enExample) |
| IL (1) | IL245038B (enExample) |
| LT (1) | LT3057965T (enExample) |
| ME (1) | ME03377B (enExample) |
| MX (1) | MX359069B (enExample) |
| NZ (1) | NZ718744A (enExample) |
| PL (1) | PL3057965T3 (enExample) |
| PT (1) | PT3057965T (enExample) |
| RS (1) | RS58413B1 (enExample) |
| SG (1) | SG11201602783SA (enExample) |
| SI (1) | SI3057965T1 (enExample) |
| SM (1) | SMT201900124T1 (enExample) |
| TR (1) | TR201902875T4 (enExample) |
| TW (1) | TWI659952B (enExample) |
| WO (1) | WO2015054793A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2417127B1 (en) | 2009-04-06 | 2014-02-26 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| PT2556071T (pt) | 2010-04-06 | 2016-11-22 | Univ Health Network | Inibidores de quinase e seus usos no tratamento de cancro |
| HRP20190564T1 (hr) | 2013-10-18 | 2019-05-17 | University Health Network | Sol i kristalni oblici inhibitora plk-4 |
| CN111225670A (zh) * | 2017-09-08 | 2020-06-02 | 大学健康网络 | 抑制Polo样激酶4的组合疗法 |
| EP3959209A4 (en) * | 2019-04-24 | 2022-12-28 | University Health Network | S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE |
| TWI880995B (zh) * | 2019-12-06 | 2025-04-21 | 加拿大健康網路大學 | 急性骨髓性白血病或骨髓發育不良症候群的治療 |
| MX2023013225A (es) | 2021-05-11 | 2024-01-15 | Oric Pharmaceuticals Inc | Inhibidores de la cinasa 4 similar a polo. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2483323A (en) * | 1945-08-01 | 1949-09-27 | Kay Fries Chemicals Inc | Method of preparing phenyl ethyl alcohol |
| US7205328B2 (en) | 2002-10-21 | 2007-04-17 | Irm Llc | Oxindoles with anti-HIV activity |
| DE102005005395A1 (de) * | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| GB0606234D0 (en) * | 2006-03-29 | 2006-05-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutically acceptable salts and polymorphic forms |
| WO2008118097A1 (en) * | 2007-03-23 | 2008-10-02 | Agency For Science, Technology And Research | Palladium catalysts |
| US20110201818A1 (en) * | 2007-09-25 | 2011-08-18 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| JP2011506494A (ja) * | 2007-12-21 | 2011-03-03 | ユニバーシティ・ヘルス・ネットワーク | 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体 |
| EP2417127B1 (en) | 2009-04-06 | 2014-02-26 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| ES2660146T3 (es) | 2009-04-29 | 2018-03-21 | Nerviano Medical Sciences S.R.L. | Sales del inhibidor de cdk |
| PT2556071T (pt) | 2010-04-06 | 2016-11-22 | Univ Health Network | Inibidores de quinase e seus usos no tratamento de cancro |
| WO2012000103A1 (en) | 2010-07-02 | 2012-01-05 | University Health Network | Methods of targeting pten mutant diseases and compositions therefor |
| WO2012048411A1 (en) * | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| KR20130105675A (ko) * | 2010-11-25 | 2013-09-25 | 라티오팜 게엠베하 | 아파티닙의 신규 염 및 다형 |
| US9580390B2 (en) * | 2011-10-12 | 2017-02-28 | University Health Network | Indazole compounds as kinase inhibitors and method of treating cancer with same |
| ES2908200T3 (es) | 2013-10-18 | 2022-04-28 | Univ Health Network | Tratamiento para el cáncer de páncreas |
| HRP20190564T1 (hr) | 2013-10-18 | 2019-05-17 | University Health Network | Sol i kristalni oblici inhibitora plk-4 |
-
2014
- 2014-10-17 HR HRP20190564TT patent/HRP20190564T1/hr unknown
- 2014-10-17 ME MEP-2019-97A patent/ME03377B/me unknown
- 2014-10-17 PT PT14854037T patent/PT3057965T/pt unknown
- 2014-10-17 EP EP14854037.0A patent/EP3057965B1/en active Active
- 2014-10-17 CA CA2926845A patent/CA2926845C/en active Active
- 2014-10-17 TR TR2019/02875T patent/TR201902875T4/tr unknown
- 2014-10-17 KR KR1020167012155A patent/KR20160070106A/ko not_active Ceased
- 2014-10-17 NZ NZ718744A patent/NZ718744A/en unknown
- 2014-10-17 DK DK14854037.0T patent/DK3057965T3/en active
- 2014-10-17 SG SG11201602783SA patent/SG11201602783SA/en unknown
- 2014-10-17 SI SI201431110T patent/SI3057965T1/sl unknown
- 2014-10-17 ES ES14854037T patent/ES2718603T3/es active Active
- 2014-10-17 CN CN201480064037.9A patent/CN105764899B/zh active Active
- 2014-10-17 TW TW103135953A patent/TWI659952B/zh active
- 2014-10-17 EA EA201690755A patent/EA031569B1/ru not_active IP Right Cessation
- 2014-10-17 SM SM20190124T patent/SMT201900124T1/it unknown
- 2014-10-17 WO PCT/CA2014/051001 patent/WO2015054793A1/en not_active Ceased
- 2014-10-17 KR KR1020217036751A patent/KR102395737B1/ko active Active
- 2014-10-17 LT LTEP14854037.0T patent/LT3057965T/lt unknown
- 2014-10-17 JP JP2016524077A patent/JP6492072B2/ja active Active
- 2014-10-17 US US15/029,373 patent/US9884855B2/en active Active
- 2014-10-17 CN CN202110510808.4A patent/CN113248486A/zh active Pending
- 2014-10-17 RS RS20190269A patent/RS58413B1/sr unknown
- 2014-10-17 AU AU2014336929A patent/AU2014336929B9/en active Active
- 2014-10-17 KR KR1020227015022A patent/KR20220063299A/ko not_active Ceased
- 2014-10-17 PL PL14854037T patent/PL3057965T3/pl unknown
- 2014-10-17 HU HUE14854037A patent/HUE043194T2/hu unknown
- 2014-10-17 MX MX2016004963A patent/MX359069B/es active IP Right Grant
-
2016
- 2016-04-11 IL IL24503816A patent/IL245038B/en active IP Right Grant
-
2018
- 2018-02-01 US US15/886,104 patent/US10392374B2/en active Active
-
2019
- 2019-03-22 CY CY20191100336T patent/CY1121484T1/el unknown
- 2019-04-19 US US16/389,119 patent/US10472353B2/en active Active
- 2019-11-06 US US16/675,609 patent/US10919886B2/en active Active
-
2021
- 2021-02-10 US US17/172,511 patent/US11667627B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11667627B2 (en) | Salt and crystal forms of PLK-4 inhibitor | |
| AU2014336929A1 (en) | Salt and crystal forms of PLK-4 inhibitor | |
| US10815221B2 (en) | Crystal forms of an androgen receptor antagonist, preparation method and use thereof | |
| US11878980B2 (en) | Solid forms of TTK inhibitor | |
| JP2021523120A (ja) | セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態 | |
| CN108699094B (zh) | 一种钠依赖性葡萄糖共转运蛋白抑制剂的胺溶剂合物及其制备方法和应用 | |
| SG11202111003UA (en) | Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate | |
| EP3476843A1 (en) | Pyrimidine compound, chloride salt thereof, and manufacturing and application of same | |
| HK1227404B (en) | Salt and crystal forms of plk-4 inhibitor | |
| HK1227404A1 (en) | Salt and crystal forms of plk-4 inhibitor | |
| EA044843B1 (ru) | Кристаллическая форма ингибитора plk4 |